A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...

The Warburg effect describes how cancer cells switch from oxidative phosphorylation to glycolysis even in oxygen-rich ...

The FDA approval of denileukin diftitox (Lymphir) marked a significant shift in this paradigm. As a first-in-class immunotoxin, it employs a dual-action mechanism: directly targeting interleukin-2 (IL ...

Exelixis, Inc. and Natera , a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 ...

Immune cells work to fight infection and other diseases. Different subsets work together to elicit a healthy immune response; ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to ...

A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the ...